Find out if their COPD is genetic by screening for alpha1-antitrypsin (AAT) deficiency

AlphaID™ offers fast, free, and accurate ways to screen patients for alpha-1. By screening, you can help ensure patients receive an accurate diagnosis and the right treatment plan.

AlphaID Cheek Swab

Healthcare providers can use the AlphaID cheek swab to screen patients with COPD and/or treatment-resistant asthma for alpha-1.


Healthcare providers can use AlphaID CONFIRMTM, a simple fingerstick, to test for or confirm an alpha-1 diagnosis.

AlphaID at Home

Patients can use the AlphaID at Home cheek swab on their own to screen for alpha-1 by ordering a free kit.

The receipt of these free testing services does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer.

>90% of patients with AAT deficiency are undiagnosed1

AAT deficiency, also called alpha-1 or genetic COPD, is a relatively common but widely underrecognized inherited condition that increases the risk of early-onset COPD.2-4 Alpha-1 may be a contributing cause in up to 3% of COPD cases in the United States.3,5

Follow the screening guidelines

Major respiratory organizations recommend screening for alpha-1 in all of your patients with COPD and treatment-resistant asthma.6-10

Is AAT deficiency behind their COPD?

Primary care providers and other allied healthcare providers are likely to be the first point of contact for patients with COPD.2 Your role is vital to increasing identification and diagnosis of AAT deficiency, an inherited, potentially fatal condition.2-4 Genetic testing is required to detect and diagnose AAT deficiency.5

AlphaID genetic screening test that detects the 14 most prevalent alleles associated with AAT deficiency

AlphaID makes screening fast, free, and accurate*

AlphaID is an advanced genetic screening test that detects the 14 most prevalent alleles associated with AAT deficiency.13

Up Next: Alpha-1 & COPD

COPD, chronic obstructive pulmonary disease.
AAT, alpha-1 antitrypsin.


  1. Brantly, M., Campos, M., Davis, A.M. et al. Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet J Rare Dis. 15, 96 (2020). Accessed September 8, 2023.
  2. Campos MA, Wanner A, Zhang G. Snadhaus RA. Trends in the diagnosis of symptomatic patients with a1-antitrypsin deficiency between 1968 and 2003. CHEST. 2005;128(3):1179-1186.
  3. Stoller JK. Myths and misconceptions about a1-antitrypsin deficiency. Arch Intern Med. 2009; 169(6): 546-550.
  4. Stoller JK, Aboussouan LS. A review of alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185(3): 246-259.
  5. Alpha-1 Foundation. Lung disease. Accessed September 23, 2023.
  6. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016; 3(3):668-682.
  7. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med.  2003:168(7): 818-900.
  8. Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management, and prevention. 2023 report. Accessed August 29, 2023.
  9. World Health Organization. Alpha 1-antitrypsin deficiency memorandum from WHO meeting. Bull World Health Org. 1997;75(5):397-415.
  10. CHEST Foundation. Diagnosing AAT Deficiency. Accessed September 8, 2023.
  11. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutropils: implications for pulmonary emphysema in a1-antitrypsin deficiency. J Clin Invest. 1999;104(3):337-344.
  12. Data on file, Alpha-1 Genetics Laboratory, Grifols.
  13. A1AT Genotyping Test package insert. Progenika Biopharma.